65,437 trials
B-cell Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 2; 2; 4; 3 patients
Type 2 Diabetes Mellitus
Primary: Reduction of HbA1c From Baseline — -1.29; -0.55; -0.34 Percent (%)
Diabetes · Diabetes Mellitus, Type 2
Primary: Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. — -1.44; -1.91; -1.28 Percentage of glycosylated haemoglobin
Chronic Hepatitis B
Primary: Number of Participants Who Had Access to, and Received the Intervention — 24 Participants
Congenital Heart Disease
Primary: Total Morphine Dosage — 0.9; 0.23 mg/kg
Septic Shock
Primary: Proportion of Patients Maintaining Target Mean Arterial Pressure (MAP) (>60 mmHg) With no Open Label NE (Norepinephrine) — 0.0; 47.1; 0.0; 10.0 Percentage of patients
Glaucoma
Primary: Intraocular Pressure in Sitting and Supine Positions. — 18.5; 19.4; 22.2; 22.8 mmHg
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 — 123; 139; 34; 31 Participants — p=0.238
Alcoholism
Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…
Diabetic Foot
Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 962.728; 985.257 Nanogram per milliltre (ng/mL) — p=0.3125
Aortic Valve Insufficiency · Aortic Valve Regurgitation · Aortic Valve Stenosis
Primary: Number of Participants With Adverse Events — 6; 14; 53; 10 participants
Basal Cell Nevus Syndrome
Primary: Tumor Clearance Rate Following Red or Blue Light PDT — 87.3; 99 Percentage of tumors cleared
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Prostate Cancer
Primary: Number of Patients Experiencing Dose-Limiting Toxicities — 1; 1; 0 Participants
Brain Tumor · Central Nervous System Tumor · Childhood Germ Cell Tumor
Primary: Incidence of Hearing Loss — 14; 31 Patients